NCT03223896 (NALPILO) is a Phase 2 clinical trial of Naloxone hydrochloride 20mg/ml in Gambling, sponsored by Finnish Institute for Health and Welfare.

Who is sponsoring NCT03223896?

NCT03223896 is sponsored by Finnish Institute for Health and Welfare.

What drugs are being tested in NCT03223896?

Interventions in NCT03223896: Naloxone hydrochloride 20mg/ml.

What condition does NCT03223896 study?

NCT03223896 studies Gambling, Opioid, Naloxone, Spray.

Is NCT03223896 still recruiting?

NCT03223896 is currently completed. Last updated 12 September 2019.

Last reviewed 2019-09-12 · How we verify

NCT03223896: NALPILO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray

Completed Phase 2 Last updated 12 September 2019

What this trial tests

Phase 2 trial testing Naloxone hydrochloride 20mg/ml in Gambling in 20 participants. Completed in 30 June 2017.

Timeline

14 February 2017

Primary endpoint
30 June 2017

30 June 2017

Quick facts

Lead sponsor	Finnish Institute for Health and Welfare
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	14 February 2017
Primary completion	30 June 2017
Estimated completion	30 June 2017
Sites	1 location across Finland

Drugs / interventions tested

Naloxone hydrochloride 20mg/ml — full drug profile →

Conditions studied

Gambling — all drugs for Gambling →
Opioid — all drugs for Opioid →
Naloxone — all drugs for Naloxone →
Spray — all drugs for Spray →

Sponsor

Finnish Institute for Health and Welfare

Who can join

Eligibility, any sex, with Gambling or Opioid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group B: naloxone max 16 mg/per day. Study duration 8 weeks. Brief intervention.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacological interventions for the treatment of disordered and problem gambling.
Dowling N, Merkouris S, Lubman D, Thomas S, et al · · 2022 · cited 10× · PMID 36130734 · DOI 10.1002/14651858.cd008936.pub2

Verify or expand the search:

Other Finnish Institute for Health and Welfare trials

Trials by the same sponsor.

NCT06904469 — Ostrobothnia Digital Clinic Experiment · NA · active not recruiting
NCT05565170 — Digitally Supported Lifestyle Programme to Promote Brain Health Among Older Adults · NA · active not recruiting
NCT05117333 — Reminders, Cost Sharing, and Healthcare Use · NA · completed
NCT03332966 — Youth Experiences and Health Study · recruiting
NCT03748160 — Herd Immunity and Influenza Vaccine Uptake · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03223896 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Finnish Institute for Health and Welfare
Last refreshed: 12 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03223896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing